Sequoia Joins $32M Round In China’s Oncology-Focused EOC Pharma

For Digital Subscribers Only

China’s Taikang Investment has led a US$32 million series B round in EOC Pharma Group, an oncology-focused development company, through its healthcare and consumer industry-focused Shandong State-owned Taikang Industry Development Fund.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

Caishen.Co - Primary Data for China Secondary Investment and Stock Markets

RELATED NEWS



LEAVE A REPLY